Cytomos’ AuraCyt™ platform has the potential to revolutionise cell analytics, which in turn could transform life sciences. The platform closely monitors a broad range of cell features simultaneously and collects data on intrinsic cellular properties in near-real-time, delivering label-free, unbiased, consistent, accurate and reliable predictive cell analytics. AuraCyt™ could accelerate biological drug discovery and development, streamline biologics manufacturing (with near-real-time monitoring potential), and provide better prospects for delivering automation in the future production of complex biologics such as monoclonal antibodies and cell and gene therapies.
Cytomos will be showcasing its novel technology on its stand ST15 in the Start-up Zone of this year’s London Biotechnology Show, which takes place at Olympia West, London (UK) on 8–9 May 2024. The London Biotechnology Show is considered a premier biotechnology event in the UK and the broader European region, expediting the progress of biotechnology for revolutionising medical and healthcare sectors globally.
Cytomos CEO David Rigterink commented, “We are excited to provide a sneak preview of Celledonia™ prior to its launch in June 2024. Cytomos has been building on its past decade’s profound Deep tech R&D progress, and the launch of this brand-new benchtop instrument marks the start of a seismic disruption to the single cell analytical market.”
“The true long-term potential of complex therapeutics is about to be unlocked by next generation technologies that overcome the limitations and challenges of conventional tools,” added Dr Fernanda Masri, the company’s Chief Commercial and Innovation Officer, and former Head of Manufacturing Innovation at Cell and Gene Therapy Catapult. “New TechBio tools like Celledonia™ are going to revolutionise biotech, from development to manufacturing.”
If you are attending the London Biotechnology Show 2024, be sure to stop at the Cytomos exhibition stand ST15 to meet the team and see their ground-breaking technology for yourself. For more information, visit www.cytomos.com.
01 May 2024
[gravityform id="1" title="false"]